Condra K S, Mendenhall W M, Morgan L S, Marcus R B
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385 USA.
Radiat Oncol Investig. 1997;5(6):300-4. doi: 10.1002/(SICI)1520-6823(1997)5:6<300::AID-ROI6>3.0.CO;2-1.
The purpose of this study was to evaluate the efficacy of adjuvant 32P for patients with high-risk, early-stage ovarian carcinoma. Twenty-five patients underwent apparent complete resection followed by 32P (15 mCi) at the University of Florida between 1976 and 1993. Minimum and median follow-up times were 3 and 8 years, respectively. The rate of local control at 10 years was 83%. Four of the 5 patients who experienced recurrent disease had a component of intra-abdominal disease at the time of relapse. The absolute and cause-specific survival rates at 10 years were 68% and 82%, respectively. There were no severe acute complications. Five patients experienced significant late complications, including chronic abdominal cramping that was treated conservatively (3 patients) and small bowel obstruction necessitating surgical intervention (2 patients). Adjuvant 32P results in disease control and survival rates that are similar to those observed after adjuvant chemotherapy. However, the risk of late complications, particularly small bowel obstruction, is higher.
本研究的目的是评估辅助性³²P对高危早期卵巢癌患者的疗效。1976年至1993年间，25例患者在佛罗里达大学接受了看似完全切除，随后接受³²P（15毫居里）治疗。最短和中位随访时间分别为3年和8年。10年时的局部控制率为83%。5例复发患者中有4例在复发时有腹腔内疾病成分。10年时的绝对生存率和病因特异性生存率分别为68%和82%。无严重急性并发症。5例患者出现明显的晚期并发症，包括采用保守治疗的慢性腹部绞痛（3例）和需要手术干预的小肠梗阻（2例）。辅助性³²P导致的疾病控制率和生存率与辅助化疗后的观察结果相似。然而，晚期并发症的风险，尤其是小肠梗阻的风险更高。
